• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pear Therapeutics says new data backs its prescription digital therapeutic for insomnia

March 15, 2022 By Sean Whooley

Pear TherapeuticsPear Therapeutics (Nasdaq:PEAR) today announced data from two studies that highlight the effectiveness of its chronic insomnia treatment.

Boston-based Pear Therapeutics designed its Somryst prescription digital therapeutic (PDT) to address the underlying issues of chronic insomnia by delivering cognitive behavioral therapy for insomnia (CBTi), training the body to sleep. The nine-week PDT can be used on a mobile device, such as a smartphone or tablet as the only FDA-authorized therapeutic that delivers guideline-recommended first-line treatment for chronic insomnia.

According to a news release, results from the two studies were presented at World Sleep 2022, the International Congress of World Sleep Society, on March 15 in Rome.

“Today, many people face barriers to accessing care so the opportunity to provide patients with 24/7 virtual access to proven treatment options is more important than ever,” Pear Therapeutics CMO and Head of Development Dr. Yuri Maricich said in the release. “It’s critical to examine the impact of prescription digital therapeutics among people with chronic insomnia, particularly given the toll lack of sleep can take on day-to-day activities and overall quality of life, including leading to depression, suicidality, hypertension and even heart attacks.”

Interim data from the DREAM study found that, in 779 patients who completed end-of-treatment, the population achieved statistically significant and clinically meaningful reductions in insomnia severity, sleep onset latency and wake-after-sleep onset from baseline to post-treatment at nine weeks.

Among the 193 patients who completed the six-month follow-up, significant improvements in all three of those categories were maintained.

In an additional study evaluating older adults (55 years old and above) with chronic insomnia, patients used an earlier version of Somryst that was tailored for older adults. Most participants were female (68.5%) at an average age of 66.3 years old with 13.5 years of sleep difficulties.

The majority (85%) of the 311 older adults with insomnia completed all six treatment cores in the study, achieving significant reductions in insomnia severity, with similar patterns in sleep onset latency and wake-after-sleep onset, along with sleep efficiency and sleep quality.

“These results provide strong evidence that older adults living with insomnia both use and obtain significant benefits from an interactive, remote program to treat their chronic insomnia, without needing special assistance,” University of Virginia School of Medicine Professor and Director of the Center for Behavioral Health and Technology Lee Ritterband said. “These results demonstrate the value of remote interventions for chronic insomnia for older adults living with insomnia who may not otherwise have access to clinically validated treatment options like CBTi.”

Filed Under: Clinical Trials, Featured, Neurological, Technology Tagged With: Pear Therapeutics

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS